NATCO Pharma to Consider Demerger of Agrochemical Business in Board Meet on March 24

NATCO Pharma Ltd announced on Wednesday that its board of directors will convene on March 24 to evaluate a proposed scheme of arrangement. 

Demerger of Agrochemical Business

The plan involves spinning off its agrochemicals division into its wholly owned subsidiary, Natco Crop Health Sciences Ltd, on a going concern basis. The company further informed that its trading window for securities will remain closed from March 19 to March 26, reopening on March 27, in compliance with insider trading norms.

In a recent development, NATCO received approval from the Central Drugs Standard Control Organisation (CDSCO) for its semaglutide injection and is targeting a launch in the Indian market later this month.

NATCO Pharma Q3FY26 Earnings Highlights

On the financial front, NATCO reported consolidated revenue of ₹705.4 crore for the quarter ended December 31, 2025, compared to ₹651.1 crore in the corresponding period last year. EBITDA (including other income) stood at ₹216.8 crore, translating to a margin of 30.7%, while consolidated net profit came in at ₹151.3 crore.

Its associate company, Adcock Ingram Holdings Ltd, recorded revenue of ₹2,464 crore and a profit after tax of ₹198 crore for the first half of its financial year ending December 31, 2025. NATCO’s share of profit from this associate, for the period between November 10 and December 31, 2025 (at a 35.75% stake), amounted to ₹29.65 crore. After accounting for a one-time amortisation charge of ₹18.75 crore, the net contribution reflected in NATCO’s financials stood at ₹10.90 crore.

Additionally, the company’s board declared an interim dividend of ₹1.50 per equity share (face value ₹2) for Q3 FY26.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.